RxDoctor Payments Data

Mark Chalem, MD

Psychiatry · Spokane, WANPI 1083830848

Payments from drug & device makers

$1,076in general payments, 2019–2025

Across 76 payments — averaging $14.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$250
  • AbbVie$204
  • Otsuka America Pharmaceutical, Inc.$143
  • Johnson & Johnson$98
  • Takeda Pharmaceuticals U.S.A., Inc.$67
  • Teva Pharmaceuticals USA, Inc.$60
  • plus $253 from 8 others

What the payments were for

  • Food & beverage$1,01294%
  • Education$636%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,076 in reported general payments places this provider in the 85th percentile of 576 psychiatry providers in Washington.

See all psychiatry providers in Washington

Medicare billing

Part B allowed, 2024
$121,899
Medicare patients
112
Services billed
1,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate46$378,233
RexultiBrexpiprazole84$167,869
AustedoDeutetrabenazine11$151,407
TrintellixVortioxetine Hydrobromide52$26,317
VraylarCariprazine Hcl14$19,016
AuvelityDextromethorphan Hbr/Bupropion17$16,612
VyvanseLisdexamfetamine Dimesylate21$10,244
Bupropion XlBupropion Hcl325$8,905
Quetiapine Fumarate259$8,708
Duloxetine Hcl232$6,831
Clozapine89$5,764
Aripiprazole129$4,807
Lamotrigine255$4,721
Buspirone Hcl149$4,602
Oxcarbazepine52$4,490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$44$378,23346 claims
Otsuka America Pharmaceutical, Inc.Rexulti$143$167,86984 claims
Teva Pharmaceuticals USA, Inc.Austedo$60$151,40711 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$67$36,56173 claims
AbbVieVraylar$204$19,01614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 576 psychiatry providers in Washington.

Other psychiatry in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →